SCNLF (Scancell Holdings) Short Interest


SCNLF Scancell Holdings PLC SCNLF
20 GF Score
Price $0.28
! 2 Warning Signs
View Full Analysis

What is Scancell Holdings Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

SCNLF vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Scancell Holdings's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scancell Holdings Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scancell Holdings's Short Interest distribution charts can be found below:

* The bar in red indicates where Scancell Holdings's Short Interest falls into.


SCNLF
20GF Score
Scancell Holdings PLC SCNLF
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scancell Holdings Business Description

Other Exchanges SCLP:UKSCP:Germany
Address Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
20GF Score

Get the complete analysis for SCNLF

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price